A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
Trial status:Study Complete
Trial ID:
GO40558
NCT ID:
EudraCT ID:
EU Trial (CTIS) Number:
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
Genentech, Inc.
Study Complete
Trial Details
This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.
Medical Condition
Trial Drug
See more
Phase
Phase 2
Type
Interventional
Estimated Enrolment
131
Estimated Trial Date
Jan 2019 - Jan 2025
Trial Participant Requirements
Age
18+ years
Sex
Female & Male
Healthy Volunteers
No
Trial Locations
Location
Status
Location
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010
Status
Location
University of California San Diego Moores Cancer Center
La Jolla, California, United States, 92037
Status
Location
UCSF Comprehensive Cancer Ctr
San Francisco, California, United States, 94115
Status
Location
University of Colorado
Denver, Colorado, United States, 80262
Status
Location
Cancer Specialists
Jacksonville, Florida, United States, 32256
Status
Location
Moffitt McKinley Outpatient Center
Tampa, Florida, United States, 33612
Status
Go to page